Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05366257 · ClinicalTrials.gov registry record

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)

A clinical trial, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
160,602
Enrollment target

NCT05366257: Completed study, sponsored by Novartis Pharmaceuticals.

NCT05366257 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 160,602 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05366257 has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
160,602 participants
Enrollment target

Study Summary

A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with CAR-T therapy among patients with r/r Diffuse Large B-cell Lymphoma (DLBCL).

Primary Outcome

Mean length of follow up was reported to compare Health Resource Use (HRU) between IP vs. OP infusion of CAR-T therapy among patients with r/r DLBCL.

Interventions

  • OTHER CAR-T
  • OTHER Allo-HSCT cohort

Trial Details

FieldValue
Enrollment Target 160,602 participants
Start Date 2020-08-17
Est. Completion 2021-05-10
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT05366257 record still lists

NCT05366257 is an observational study that tracks outcomes without assigning an intervention. Its 160,602 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 2 interventions - of which CAR-T is the first listed.

NCT05366257 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05366257 about?

NCT05366257 is a clinical study titled "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)". A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with CAR-T therapy among patients with r/r Diffuse Large B-c...

What is the current status of trial NCT05366257?

This trial is currently completed. The enrollment target is 160,602 participants. The study started on 2020-08-17. Estimated completion is 2021-05-10.

What interventions are being tested in trial NCT05366257?

The interventions under investigation include: CAR-T (OTHER), Allo-HSCT cohort (OTHER).

Who is sponsoring clinical trial NCT05366257?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06917339 · 156,000 participants

    Retrospective Analyses of TrakStar Database

  • NCT06232551 · 152,000 participants · NA

    Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

  • NCT06090578 · 180,000 participants · NA

    TabCAT Brain Health Assessment in Primary Care

  • NCT05994482 · 130,000 participants

    Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05366257, the US trial registry maintained by the National Library of Medicine. NCT05366257 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.